Gilead posts strong Q4, raises 2026 product-sales guidance

Transcript intelligence

What changed

Compared with the prior-quarter analysis, management continued to report confident execution but added clearer evidence of YES2GO payer expansion, identified up to four 2026 launches, and highlighted an expected 10% 2026 decline in cell-therapy revenue from competitive pressure.

Guidance delta

Management raised 2026 product-sales guidance to $29.6–30 billion, while noting modest pricing headwinds from Medicare Part D redesign and ACA changes.

Key takeaways

• Management described strong 2025 performance across HIV, liver disease and oncology, with total product sales of $28.9 billion.
• YES2GO reached about 90% payer coverage with zero-dollar co-pay within six months of launch.
• The 2026 pipeline includes up to four launches, including Viclen, Anidocel, first-line Trodelvy and bruleviratide.
• Cell-therapy revenue is expected to decline about 10% in 2026 as new competitors enter the market.
• Management emphasized expense discipline, share repurchases and approximately $1 billion a year in early-stage licensing and collaboration activity.

Management priorities

• Expand HIV prevention and treatment products, including YES2GO and future lenacapavir-based regimens.
• Execute planned 2026 launches and Phase III readouts across HIV prevention, oncology and liver disease.
• Manage competitive pressure in cell therapy and HIV prevention.
• Maintain expense discipline and continue strategic M&A and early-stage licensing.